Welcome to our dedicated page for Ligand Pharmaceuticals news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharmaceuticals stock.
Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand (Nasdaq: LGND) reported that its senior management will participate in three investor events in September 2026: Wells Fargo Healthcare Conference in Boston on September 8 at 12:45 p.m. ET, Citi 2026 Biopharma Back to School Conference in New York on September 10 at 9:20 a.m. ET, and H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14 at 10:00 a.m. ET. Management also plans to hold one-on-one meetings with investors and attendees during these conferences.
Orchestra BioMed (Nasdaq: OBIO) reported second quarter 2026 results and updates on its pivotal cardiovascular programs. The BACKBEAT global pivotal trial of AVIM Therapy, conducted with Medtronic, is on track to reach 284 evaluable randomized patients by the end of Q3 2026, with primary endpoint data presentation targeted for Q2 2027. The Virtue SAB pivotal trial for coronary in-stent restenosis continues to progress with additional site activations and patient enrollment, and AVIM Therapy received a second FDA Breakthrough Device Designation.
According to Orchestra BioMed, Q2 2026 cash, cash equivalents and marketable securities totaled $110.0 million, including $35 million in new strategic capital from Medtronic and Ligand, providing projected runway into Q4 2027. Q2 revenue was $0.1 million, research and development expenses were $16.6 million (up 20% year over year), selling, general and administrative expenses were $5.8 million (down 7%), and net loss attributable to common stockholders was $24.1 million, or ($0.38) per share. The company was added to the Russell 3000 and Russell 2000 indexes and plans an R&D Day on November 12, 2026, in New York City.
Ligand (Nasdaq: LGND) reported second-quarter 2026 revenue and income of $63.7 million, up 34% year-over-year, driven by a 32% increase in royalty revenue to $48.0 million, mainly from Travere’s Filspari, Pelthos’ Zelsuvmi, and Merck’s Ohtuvayre.
GAAP net income was $48.5 million ($2.22 per diluted share) versus $4.8 million a year ago. Adjusted net income rose to $50.8 million ($2.37 per diluted share), up 59% and 48% respectively. For the first half, royalties grew 42% to $91.0 million, with adjusted EPS up to $4.00.
Ligand completed a $700 million 0.00% convertible note offering due 2031, ending June with $1.36 billion in cash and investments. After quarter-end it closed the XOMA Royalty acquisition, more than doubling its portfolio to over 200 royalty assets. 2026 revenue guidance is reaffirmed, while the low end of adjusted EPS guidance is raised to $9.00–$9.50.
Ligand Pharmaceuticals (Nasdaq: LGND) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 8:30 a.m. Eastern time to discuss results and provide a general business update.
The call offers U.S. local and toll-free dial-in options, international access via global dial-in numbers using Meeting ID 780702347, and a live and replay webcast. Ligand describes itself as a royalty aggregator with economic interests in more than 200 development and commercial-stage biopharmaceutical assets and also licenses its Captisol and NITRICIL technologies.
Ligand (Nasdaq: LGND) completed its acquisition of biotechnology royalty aggregator XOMA Royalty for $39.00 per share in cash, implying total equity value of approximately $739 million. XOMA Royalty stockholders also received one non-transferable contingent value right (CVR) per share, tied to 75% of net proceeds from certain pending litigation at XOMA Royalty.
According to Ligand, the deal adds seven commercial products, including VABYSMO, OJEMDA and MIPLYFFA, plus 14 late-stage programs and more than 100 additional development and commercial-stage assets. Ligand’s royalty portfolio now exceeds 200 assets across commercial, clinical and preclinical stages. The transaction closed on the original timeline and is expected to be immediately accretive, adding about $0.50 and $1.50 per share to projected 2026 and 2027 adjusted EPS, respectively. Ligand plans to provide an updated five-year outlook at its Investor Day on December 8, 2026. XOMA Royalty common stock has ceased trading on the Nasdaq Global Market.
Ligand (Nasdaq: LGND) closed a 0.00% convertible senior notes offering due 2031 with an aggregate principal amount of $700 million, including $75 million from the option exercise.
Net proceeds were about $678.2 million, allocated to note hedges, a share repurchase, and general corporate purposes.
Ligand (Nasdaq: LGND) priced an upsized private offering of $625 million aggregate principal amount of 0.0% convertible senior notes due 2031, with an option for an additional $75 million.
Net proceeds of about $605.3 million will fund convertible note hedges, a $60 million share repurchase of 228,859 shares at $262.17, and general corporate purposes, including its previously announced Xoma Royalty Corporation acquisition. The initial conversion price is approximately $334.27 per share, a 27.5% premium to the last closing price, and related warrant transactions carry a $524.34 strike price, 100% above that close.
Ligand (Nasdaq: LGND) plans a private offering of $550 million convertible senior notes due September 15, 2031, with an option for an additional $82.5 million. The notes are senior unsecured, pay semiannual interest starting March 15, 2027, and are convertible into cash and/or stock.
Ligand expects to use proceeds for convertible note hedge and warrant transactions, up to $75 million in share repurchases, and general corporate purposes, including its agreement to acquire Xoma Royalty Corporation. Hedge transactions aim to reduce conversion-related dilution, while associated warrants may be dilutive above their strike price.
Ligand (Nasdaq: LGND) will host a 2026 Investor Day in New York City on December 8, 2026, at 10:30 a.m. Eastern time at the Harvard Club.
Presentations from senior management will cover strategy, recent investment activity, the royalty portfolio, and long-term financial outlook, with a live webcast on the Investor Relations site.
Ligand (Nasdaq: LGND) announced participation in two June 2026 investor conferences. At the Stifel 2026 Boston Cross Sector 1x1 Conference, management will hold one-on-one investor meetings on June 3, 2026 in Boston.
At the Goldman Sachs 47th Annual Global Healthcare Conference, management will host a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami, followed by one-on-one meetings.